Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Ther Drug Monit. 2011 Jun;33(3):369-71. doi: 10.1097/FTD.0b013e31821a7aa3.

CYP3A5 genotype is not related to the intrapatient variability of tacrolimus clearance.

Author information

  • 1Department of Hospital Pharmacy, Clinical Pharmacology Unit, Erasmus MC, Rotterdam, the Netherlands.

Abstract

BACKGROUND:

The risk of long-term chronic allograft nephropathy and graft loss after kidney transplantation is increased in patients with a high intrapatient variability of tacrolimus (Tac) clearance.

METHODS:

To test whether this intrapatient variability is associated with an individual's CYP3A5 genotype, we measured the intrapatient variability in Tac clearance in a cohort of 208 kidney transplant recipients treated with Tac and mycophenolate mofetil.

RESULTS:

Tac dose requirement was significantly higher in patients expressing CYP3A5. However, intraindividual variability of Tac clearance was not related to CYP3A5 genotype.

CONCLUSIONS:

Intraindividual variability in Tac clearance is not related to CYP3A5 genotype. Other factors, including patient adherence, may explain the variability in Tac clearance within an individual patient over time.

PMID:
21566507
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk